Mast Therapeutics Inc (MSTX)

0.44
AMEX : Health Care
Prev Close 0.41
Day Low/High 0.41 / 0.44
52 Wk Low/High 0.21 / 0.60
Avg Volume 2.91M
Exchange AMEX
Shares Outstanding 192.84M
Market Cap 79.06M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City

Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City

Very few people expect Mast's compound to become the first, new drug for sickle cell disease in almost 20 years. That's why Mast carries a miniscule $60 million market value.

Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network

Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network

Study to be conducted with support from a grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)

Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo

Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo

-Ex vivo study results indicate that by limiting unregulated calcium entry, vepoloxamer improves calcium cycling and left ventricle (LV) function in dogs with severe heart failure

Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic

Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic

Study met its primary endpoint; AIR001 was generally well-tolerated, with no treatment-related serious adverse events

Mast Therapeutics Provides Business Update

Mast Therapeutics Provides Business Update

- Enrollment in largest-ever interventional Phase 3 trial in sickle cell disease has surpassed 90%; top-line data anticipated Q2 2016

Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions

Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions

- Repeat administration of vepoloxamer in animals with severe heart failure elicited progressively sustained improvement in left ventricle systolic function evident for at least 6 weeks

Mast Therapeutics To Host Third Quarter 2015 Financial Results And Corporate Update Conference Call

Mast Therapeutics To Host Third Quarter 2015 Financial Results And Corporate Update Conference Call

Call Scheduled Thursday, November 12, 2015 at 4:30pm ET / 1:30pm PT

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

- Study initiated with new formulation of vepoloxamer

Mast Announces Amendment To Loan And Security Agreement With Hercules Technology Growth Capital

Mast Announces Amendment To Loan And Security Agreement With Hercules Technology Growth Capital

- Hercules funds second advance of $10 million; total funding now $15 million

3 Stocks Under $10 to Trade for Big Breakouts

3 Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering breakout trades.

Mast Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting

Mast Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting

- In vitro study results indicate vepoloxamer may limit or prevent cardiomyocyte dysfunction and death due to calcium overload in heart failure

Mast Therapeutics To Host Analyst & Investor Day On October 7, 2015

Mast Therapeutics To Host Analyst & Investor Day On October 7, 2015

Company to discuss new information from ongoing EPIC Phase 3 and AIR001 Phase 2a studies and commercialization strategy for vepoloxamer

Mast Therapeutics To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call

Mast Therapeutics To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call

Call Scheduled Thursday, August 13, 2015 at 8:30am ET / 5:30am PT